MDRO Management
On this page
Direct answer
MDRO — the multidrug-resistant organism — is as much a ward-level problem as a laboratory label, and managing it means running infection control and antibiotic stewardship in parallel. The working definitions: MDR is acquired resistance to at least one agent in three or more antimicrobial classes; XDR is MDR plus susceptibility remaining to only one or two classes; pandrug-resistant means no tested agent works. The roster Indian hospitals actually face includes MRSA, vancomycin-resistant Enterococcus, ESBL and carbapenemase-producing Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii and Pseudomonas, Candida auris colonising ICU surfaces, and within the national TB programme the MDR, pre-XDR and XDR tuberculosis categories. Every one of these is managed with the same bundle: screen or surveil, isolate or cohort, enforce hand hygiene, clean the environment, remove devices early, and prescribe the narrowest effective therapy with scheduled review.
What you must remember
- Definitions to quote: MDR — non-susceptibility to at least one agent in three or more classes; XDR — MDR with remaining susceptibility to at most two classes; PDR — none; these standard definitions sit beside ICMR surveillance categories that Indian laboratories report.
- The priority organisms: MRSA (mecA/PBP2a, cefoxitin screen), VRE (vanA in Enterococcus faecium), ESBL and carbapenem-resistant Enterobacteriaceae (NDM, KPC, OXA-48), carbapenem-resistant Acinetobacter baumannii — the signature Indian ICU pathogen — and Candida auris, first described in 2009 and now persistent on Indian hospital surfaces.
- Tuberculosis grading: MDR-TB is resistance to isoniazid and rifampicin; pre-XDR adds any fluoroquinolone resistance; XDR-TB, per current WHO definitions, adds resistance to bedaquiline or linezolid — the NTEP basis for regimen choice and for molecular DR testing.
- Isolation practice: contact precautions with gloves and gown, single room or cohorting of same-organism patients, dedicated equipment, and terminal cleaning after discharge — with chlorhexidine bathing and mupirocin decolonisation used selectively for MRSA carriers undergoing surgery.
- Hand hygiene: the WHO five moments, alcohol rub as default unless spores (C. difficile) or norovirus demand soap and water — the single highest-yield intervention in every exam answer.
- Device stewardship: review central lines, urinary catheters and endotracheal tubes daily with removal criteria, because biofilms convert brief colonisation into sustained bacteraemia.
- Stewardship pair: empiric therapy de-escalated on culture reports, with an antibiotic policy and prescription audit; hospital infection control committees make these enforceable, and NABH accreditation checks the paperwork.
The first 48 hours after one CRE admission
A blood culture flags carbapenem-resistant Klebsiella on a surgical ward. The first hour is communication and placement: the patient moves to a single room or joins a CRE cohort, contact-precaution signage goes up, and dedicated stethoscope and thermometer arrive. Screening follows — groin and rectal swabs of roommates, because colonisation precedes infection and tells you whether this is importation or an established ward reservoir. The environment gets its share: daily chlorine-based cleaning of high-touch surfaces, and after discharge a terminal clean, with hydrogen peroxide vapour where available, since Acinetobacter and Candida auris survive dry surfaces for weeks. On the therapy side, the team re-justifies every line and catheter, confirms the isolate's carbapenemase mechanism if the laboratory can, and locks in a defined treatment endpoint. Finally, the discharge letter travels the organism forward — transfer calls to the receiving ward, so precautions restart on arrival instead of after the next positive culture.
Across the hospital, the same admission feeds the AMR surveillance register: one more denominator in the ICMR data that eventually redirects the empiric antibiotic policy for everyone else.
Where the exam sets traps
The commonest scenario mistake is treating colonisation. A Candida auris isolate from a surveillance swab, or a carbapenem-resistant Klebsiella from a catheter specimen in a patient without fever or pyuria, needs precautions and device removal — not antifungals or colistin. Distinguish colonisation from infection explicitly in every answer. Second trap: the definitions drift — writing "MDR means resistant to three drugs" loses the mark; it is three or more classes, not agents. Third, students prescribe vancomycin for VRE or linezolid reflexively; the exam wants the susceptibility-guided choice (daptomycin or linezolid per source and susceptibility) plus the recognition that VRE mostly infects the already-hospitalised. For tuberculosis, quote the current ladder correctly — MDR, then pre-XDR with fluoroquinolone resistance, then XDR with additional bedaquiline or linezolid resistance — because older definitions (which required injectable resistance) still circulate in outdated guides and are deliberately used as distractors.
Frequently asked questions
What defines an organism as XDR rather than MDR?
XDR isolates remain susceptible to only one or two antimicrobial classes, whereas MDR denotes non-susceptibility to at least one agent in three or more classes.
Which precautions apply to a patient colonised with CRE?
Contact precautions — gown and gloves, single room or cohorting, dedicated equipment, hand hygiene at WHO's five moments — plus screening of contacts and terminal environmental cleaning.
How is XDR tuberculosis defined under current WHO criteria?
Tuberculosis resistant to isoniazid and rifampicin, plus any fluoroquinolone, plus bedaquiline or linezolid — the NTEP category determining longer individualised regimens.
Why is Candida auris an infection-control emergency?
It colonises skin persistently, survives on dry surfaces for weeks, withstands common disinfectants and resists multiple antifungals, producing sustained ICU outbreaks.
What is antimicrobial de-escalation in practice?
Narrowing or stopping empiric broad-spectrum therapy once culture and susceptibility results return, paired with daily review of indications, doses and durations to limit resistance selection.